Zofingen (Switzerland) and Ballerup (Denmark). – Siegfried Holding AG and Symphogen A/S announced today they have entered into an agreement for the manufacturing – fill and finish – activities associated with Symphogen A/S development programs.
“We are delighted to partner with Symphogen for the production of their antibody finish products,” Andrea Como, Head Business Development Drug Product EU & ROW said, “and glad that they selected our award winning facility located in Hameln, Germany, equipped with a brand-new, low-loss filling line specifically designed for sterile biologics. Symphogen is developing therapies against cancers and we are proud to be part of this journey”.
Chief Manufacturing Officer, Mads Laustsen, commented:” We are happy to engage into the collaboration with Siegfried Hameln. The facility in Hameln is well-suited to manufacture finished antibody products in small and larger scale with low losses, which make them an ideal partner for both early and late stage products”.
Chief Communications Officer
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Contact Business Development:
Head of Business Development Drug Product
Tel. +41 62 746 15 24
Siegfried Holding AG
Untere Bruehlstrasse 4
Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use with headquarters in Ballerup, Denmark and an additional facility in Summerville, New Jersey, USA. At the end of 2016, Symphogen reported that the company has raised € 317 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 100 people, most of who are based at Symphogen’ s facilities in Copenhagen. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product.
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.